Company intelligence / Profile preview

N4 Pharma

Ownership: Private
Development stage: Preclinical

Overview

N4 Pharma is developing Nuvec®, a silica nanoparticle delivery system that has been proven to protect and deliver nucleic acid payloads into cells. The technology has shown strong dose response curves with siRNA, demonstrating significant cellular transfection at low doses, which can reduce the amount of expensive siRNA needed to be effective.

Therapeutic areas: Oncology
Modalities: siRNADNARNAgene therapy
Industry: Drug Discovery Services

Drug pipeline

2 assets

N4 101

Pre-clinical

Indications: Inflammatory Bowel Disease

1 more asset in the full pipeline.

Partnerships

University of Queensland (patent rights)

Beyond the preview

Go deeper on N4 Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on N4 Pharma.